MedTrace Logo

Arterial Spin Labeling (ASL) MRI for Cognitive Decline

NCT01727622 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2020-09-28

No results posted yet for this study

Summary

The purpose of this study is to determine the value of Arterial Spin Labeling (ASL) MRI, a measure of blood flow to the brain, in Mild Cognitive Impairment (MCI) and compare it to existing measures. In particular, the investigators will compare ASL MRI to Positron Emission Tomography (PET/CT), which measures brain metabolism reflecting how well cells in a patient's brain are functioning. In addition, the investigators will assess the relationship of these measures to specific protein levels associated with Alzheimer's Disease in the patient's cerebrospinal fluid (the fluid that surrounds the brain and spinal cord) obtained by lumbar puncture. By comparing the information that is available from these procedures to the patient's performance on cognitive tests, the investigators hope to learn which procedures most accurately reflect and assist in determination of the potential causes of cognitive difficulties that arise with MCI, and thus, which are most useful in the clinical setting. In particular, PET scans have been found to be very useful in diagnosis of MCI and Alzheimer's Disease, but the investigators want to find out if they can get the same, or better, information from an ASL MRI scan, which is less expensive and easier to acquire.

Conditions

Interventions

DRUG

FDG-PET

Diagnostic: FDG-PET imaging to examine neuronal health

OTHER

ASL-MRI

Arterial-Spin Labeled MRI to examine cerebral blood flow

PROCEDURE

Lumbar Puncture

Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.

Sponsors & Collaborators

Principal Investigators

  • David A Wolk, MD · University of Pennsylvania

Eligibility

Min Age
55 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2018-05-11
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01727622 on ClinicalTrials.gov